MEGIN, a leader in functional neuroimaging technology, made a significant announcement today by unveiling MEG Maps™, a cutting-edge neuroimaging scanner platform. All the components of this platform have received FDA 510(k) clearance, marking a major step forward in the field of neuroscience.

MEG Maps™ has been specifically designed to push the boundaries of neuroscience by augmenting the performance limitations of traditional MR imaging modalities and providing neuroscientists, neurologists and oncologists with a more advanced and precise functional imaging tool.

MEG Maps™ represents MEGIN’s most advanced MEG imaging solution, providing the ability to map the brain in real time, thus opening up possibilities of a wide range of applications in neuro and cognitive sciences. Designed together with MEGIN’s customers, MEG Maps™ will empower both clinicians and researchers to unravel the mysteries of the human brain and improve diagnosis as well as treatment of neurological conditions.

By enabling clinicians and researchers to identify minuscule magnetic fields generated during brain cell activity and capturing bioelectric fields with millisecond precision, MEG Maps™ offers insights into the intricate involvement of different brain regions in its various processes. When paired with hemodynamic data obtained from MR technology, this capability has the potential to revolutionize our understanding of brain functionality, paving the way for groundbreaking discoveries in the realm of neuroscience.

Craig Shapero, the CEO of MEGIN, emphasized that MEG Maps™ is a user-friendly image-based foundation upon which MEGIN will expand the utilization of MEG into new, exciting applications. This platform transforms the field of neurosciences with the unique combination of spatial and temporal resolution not available in other neuroimaging technologies. “The implications of MEG Maps™ on patient outcomes and our comprehension of the human brain are profound and hold great promise for future developments in the field of neuroscience.”

MEGIN continues to lead in reshaping the landscape of functional brain imaging, with the aim of ensuring that every scientific advancement translates into meaningful health outcomes for patients worldwide.

Learn more about MEGIN online here:

Available for Sale in the United States. Pending CE marking in the European Union.



MEGIN is a global neuroscience technology company focused on developing innovative solutions for functional brain mapping for presurgical evaluation. For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology. The TRIUX™ neo provides a non-invasive, real-time view of patient-specific neural activity with millimeter accuracy and millisecond resolution, providing the most precise information currently available on the market.

Copyright 2024 © MEGIN – TRIUX™ neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries. In other geographical areas, contact your local MEGIN representative. TRIUX™ neo is intended for use as a magnetoencephalographic (MEG) device that non-invasively detects and displays biomagnetic signals produced by electrically active nerve tissue in the brain. When interpreted by a trained clinician, the data enhances the diagnostic capability by providing useful information about the location relative to the brain anatomy of active nerve tissue responsible for critical brain functions.



Sales & Media Contact
[email protected]